Aridis Pharmaceuticals In... (ARDS)
Aridis Pharmaceuticals Statistics
Share Statistics
Aridis Pharmaceuticals has 44.57M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 44.57M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 0% |
| Shares Floating | 36.9M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 2M, so 4.5% of the outstanding shares have been sold short.
| Short Interest | 2M |
| Short % of Shares Out | 4.5% |
| Short % of Float | 5.37% |
| Short Ratio (days to cover) | 0.22 |
Valuation Ratios
The PE ratio is -0.72 and the forward PE ratio is null. Aridis Pharmaceuticals's PEG ratio is 0.01.
| PE Ratio | -0.72 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | -0.91 |
| P/FCF Ratio | -0.76 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aridis Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.32, with a Debt / Equity ratio of -0.25.
| Current Ratio | 0.32 |
| Quick Ratio | 0.32 |
| Debt / Equity | -0.25 |
| Total Debt / Capitalization | -33.86 |
| Cash Flow / Debt | -4.75 |
| Interest Coverage | -79.35 |
Financial Efficiency
Return on equity (ROE) is 1.27% and return on capital (ROIC) is 167.75%.
| Return on Equity (ROE) | 1.27% |
| Return on Assets (ROA) | -2.09% |
| Return on Capital (ROIC) | 167.75% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-831,054.05 |
| Employee Count | 37 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 378K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is -26.04, so Aridis Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -26.04 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 0 |
| 200-Day Moving Average | 0.01 |
| Relative Strength Index (RSI) | 50.3 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -29.99M |
| Net Income | -30.75M |
| EBITDA | -29.51M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.64 |
Balance Sheet
The company has 4.88M in cash and 6.13M in debt, giving a net cash position of -1.25M.
| Cash & Cash Equivalents | 4.88M |
| Total Debt | 6.13M |
| Net Cash | -1.25M |
| Retained Earnings | -195.67M |
| Total Assets | 6.53M |
| Working Capital | -13.37M |
Cash Flow
In the last 12 months, operating cash flow was -29.13M and capital expenditures -82K, giving a free cash flow of -29.21M.
| Operating Cash Flow | -29.13M |
| Capital Expenditures | -82K |
| Free Cash Flow | -29.21M |
| FCF Per Share | -1.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARDS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for ARDS.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -40.63 |
| Piotroski F-Score | 4 |